All In Biotech

Free tool

FAERS Monitor: Stelara

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 125261 or its brand name (Stelara, Ustekinumab). Reports on generic versions are filed under their own applications.

Reports

103,163

Serious

61,436

60% of reports

Hospitalization

22,763

Death reported

6,203

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective14,942
  • off label use12,880
  • product dose omission issue10,242
  • fatigue6,966
  • psoriasis6,617
  • pain6,322
  • crohn^s disease5,993
  • arthralgia5,902
  • rash5,714
  • product use issue5,463
  • headache5,377
  • condition aggravated5,316
  • infusion related reaction5,233
  • rheumatoid arthritis4,920
  • diarrhoea4,806

Reports by year received

View as table
YearReports
200934
2010339
2011836
20121,456
20131,849
20141,704
20155,305
20164,517
20176,660
20188,727
201910,236
202013,325
20217,743
20229,895
202310,036
20249,237
20257,214
20264,050

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,950,996 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

FDA's data service returned an error (400). The numbers below may be missing or incomplete.
ReactionReportsPRR95% CI lowerChi-squared
infusion related reactionSignal5,23317.416.974,672
psoriasisSignal6,61710.810.656,371
rheumatoid arthritisSignal4,9209.28.934,534
product dose omission issueSignal10,2427.37.254,709
product use issueSignal5,4636.15.922,680
condition aggravatedSignal5,3163.63.510,000
off label useSignal12,8803.03.017,993
arthralgiaSignal5,9022.92.87,498
rashSignal5,7142.72.66,136
drug ineffectiveSignal14,9422.32.311,919
painSignal6,3222.12.13,761
fatigue6,9661.81.82,706
headache5,3771.81.71,784
diarrhoea4,8061.51.5880
crohn^s disease5,9930.00.01,217,239

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.